Leukemia, T-Cell clinical trials
The registry lists 137 studies for Leukemia, T-Cell across more than 10 countries. 10 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-16.
Status
- Completed
- 87
- Terminated
- 25
- Recruiting
- 9
- Status unknown
- 8
- Withdrawn
- 6
- Not yet recruiting
- 1
Phase
- Phase 1
- 70
- Phase 2
- 59
- Early Phase 1
- 4
- Phase 3
- 4
- Phase 4
- 3
Where
- United States
- 107
- China
- 16
- Italy
- 8
- Japan
- 8
- Germany
- 3
- Canada
- 3
Who runs them
National Cancer Institute (NCI) (42) · Fred Hutchinson Cancer Center (15) · Mayo Clinic (5) · Case Comprehensive Cancer Center (4) · The First Affiliated Hospital of Soochow University (3) · MP Biomedicals, LLC (3) · Beijing Boren Hospital (3) · Washington University School of Medicine (2)
Studies
Recruiting first, then most recently updated. Showing 50 of 137 — search for more.
- Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)RecruitingNCT06345027Phase 11 country
- Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or LymphomaRecruitingNCT06934382Phase 11 country
- Observatory of Prolymphocytic Leukemia TRecruitingNCT044110431 country
- CD4CAR for CD4+ Leukemia and LymphomaRecruitingNCT03829540Phase 11 country
- The OPAL Study: AVM0703 for Treatment of Lymphoid MalignanciesRecruitingNCT04329728Phase 1/21 country
- Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).RecruitingNCT07471789Phase 1/21 country
- A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1RecruitingNCT06698003Phase 21 country
- Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T CellsRecruitingNCT06420076Phase 1/21 country
- BuCy Vs. TBICy for Allo-HSCT in T-ALL PatientsNot yet recruitingNCT06673459Phase 31 country
- Precision Exercise in Children With Malignant HemopathiesRecruitingNCT04090268Not applicable1 country
- RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell LymphomaCompletedNCT00081874Phase 1/21 country
- Venetoclax Based Regimen for R/R T-ALLCompletedNCT05149378Phase 21 country
- A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD ChemotherapyCompletedNCT01184885Early Phase 11 country
- Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)CompletedNCT03792256Phase 11 country
- Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/LymphomaCompletedNCT02631746Phase 21 country
- Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/LymphomaCompletedNCT04102150Phase 21 country
- Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphomaCompletedNCT04840875Phase 11 country
- Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage LeukemiaCompletedNCT04938115Not applicable1 country
- Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic LeukemiaCompletedNCT05676710Phase 11 country
- KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)CompletedNCT01626664Phase 26 countries
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 11 country
- CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT02168140Phase 11 country
- Ipilimumab and Local Radiation for Selected Solid TumorsTerminatedNCT01769222Phase 11 country
- Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory LeukemiasWithdrawnNCT05321940Phase 1
- Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell MalignanciesSuspendedNCT04828174Phase 11 country
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid MalignanciesCompletedNCT01523223Phase 11 country
- Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell LeukemiaCompletedNCT00924170Phase 1/21 country
- Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell LymphomaCompletedNCT01336920Phase 11 country
- Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic CancerTerminatedNCT01044745Phase 21 country
- A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/LymphomaTerminatedNCT01378871Phase 21 country
- Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid MalignanciesWithdrawnNCT05513612Phase 11 country
- Ruxolitinib for Adult T-Cell LeukemiaTerminatedNCT01712659Phase 1/21 country
- Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary SyndromeCompletedNCT04185220Phase 11 country
- CAR-T Cells in the Treatment of Malignant Hematological TumorsStatus unknownNCT05619861Not applicable1 country
- LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell LymphomaTerminatedNCT04219319Phase 11 country
- LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte TumorTerminatedNCT04973527Phase 11 country
- Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/LymphomaStatus unknownNCT04689659Phase 21 country
- Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01261247Phase 21 country
- Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)CompletedNCT02689453Phase 11 country
- Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies MalignanciesStatus unknownNCT04823091Phase 11 country
- Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/21 country
- Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic MalignanciesStatus unknownNCT04264078Early Phase 11 country
- Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid MalignanciesTerminatedNCT01678443Phase 11 country
- Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 21 country
- Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLLCompletedNCT02580552Phase 11 country
- Study of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaCompletedNCT01258998Phase 21 country
- Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT01075321Phase 1/21 country
- Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers PatientsStatus unknownNCT04446130Phase 31 country
- Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell LymphomaTerminatedNCT03075553Phase 21 country
- Tipifarnib in Treating Patients With Relapsed or Refractory LymphomaCompletedNCT00082888Phase 21 country